Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Sackler Family Misled Doctors To Increase Sales Of Opioid Painkiller

(JTA) Richard Sackler and other members of his family are accused of directing their pharmaceutical firm Purdue Pharma to mislead doctors and patients about the dangers of the opioid painkiller OxyContin produced by the company.

The Massachusetts attorney general on Tuesday filed internal company communications that provide the first evidence that the Sacklers made company decisions to aggressively market OxyContin even though it is highly addictive, The New York Times reported.

Richard Sackler, a former chairman and president of Purdue Pharma and son of the company founder, Raymond, in a 2001 email advised blaming the people who had become addicted to the drug, according to the filing.

We have to hammer on abusers in every way possible, Sackler wrote when he was president of the company. They are the culprits and the problem. They are reckless criminals.

Massachusetts Attorney General Maura Healey in June sued eight members of the Sackler family and others alleging that they had misled doctors and patients about OxyContin risks. The Sacklers are among the richest families in the United States, with much of their wealth derived from sales of OxyContin, The Times reported. They are Jewish.

The filing also alleges that Richard Sackler urged sales representatives to advise doctors to prescribe the highest dosage of OxyContin because it was the most profitable.

More than 200,000 people have died in the United States from overdoses involving prescription opioids, and Purdue Pharma has been the target of numerous lawsuits. In 2007, the company and three of its top executives pleaded guilty to federal criminal charges that Purdue had misrepresented the dangers of OxyContin, and they paid $634.5 million in fines, but the Sackers were not accused of personal wrongdoing.

The company has downplayed the Sacklers’ involvement in the operations of the company. But emails as late as 2012 complain about Richard Sackler micromanagement of the company’s sales and marketing activities, according to The Times.

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version